Source: Xigem Technologies
  • Xigem Technologies (XIGM) has announced a non-brokered private placement for aggregate gross proceeds of up to $3,000,000
  • The company will issue up to 30,000,000 units at a price of $0.10 per unit
  • Xigem intends to use the net proceeds to advance its business plan and for general working capital purposes
  • Xigem Technologies is a SaaS technology platform
  • Xigem Technologies Corporation (XIGM) is unchanged, trading at C$0.09 per share at 12:45 pm ET

Xigem Technologies (XIGM) has announced a non-brokered private placement for aggregate gross proceeds of up to $3,000,000.

The company will issue up to 30,000,000 units at a price of $0.10 per unit.

Each unit will consist of one common share and one-half of a common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional share at a price of $0.20 for 18 months following the closing of the offering.

The shares and warrants will be subject to a four-month hold period.

Xigem intends to use the net proceeds to advance its business plan and for general working capital purposes.

Xigem Technologies is a SaaS technology platform, with software capable of improving the capacity, productivity, and overall remote operations for businesses, consumers, and other organizations.

Xigem Technologies Corporation (XIGM) is unchanged, trading at C$0.09 per share at 12:45 pm ET.

More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.